Relevant bibliographies by topics / Palliative treatment Japan

Academic literature on the topic 'Palliative treatment Japan'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Palliative treatment Japan.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Palliative treatment Japan"

1

Oki, Takeshi. "A Narrative Review of Problems in Learning and Practicing Palliative Care in Neurology Clinics in Japan and Proposed Solutions." Brain Sciences 12, no. 12 (December 12, 2022): 1707. http://dx.doi.org/10.3390/brainsci12121707.

Full text
Abstract:
As the understanding of the role of palliative care in neurology increases, there is the need to ensure that these developments include not only care at home and in hospitals but also in clinics. There are no reports on palliative care from neurology clinics in Japan, and this paper considers the problems and proposed solutions for improving palliative care provided at neurology clinics in Japan. In Japan, physicians in neurology clinics are extremely busy both during and after office hours with medical treatment and the preparation of various documents and are unable to conduct case conferences. Moreover, the education system for palliative care, especially for lifelong education, is not sufficient, and multidisciplinary cooperation is difficult due to the lack of specialists and their scattered locations. To improve the care provided for patients and their families, general palliative care should be included in the health insurance system with incentives and recognition, and mandatory lifelong education should be established so that all neurologists can provide palliative care. These proposals may be appropriate for other countries as palliative care in neurology is established.
APA, Harvard, Vancouver, ISO, and other styles
2

Inoue, Akira, Takuhiro Yamaguchi, Keiko Tanaka, Akihiro Sakashita, Keisuke Aoe, and Kenji Eguchi. "Effect of nationwide palliative care education program on lung cancer specialists." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e21715-e21715. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21715.

Full text
Abstract:
e21715 Background: Although palliative care has owed an essential part of cancer treatment, palliative care specialists are still insufficient. Thus in Japan, the Palliative care Emphasis program on symptom management and Assessment for Continuous Medical Education (PEACE) was launched in 2008 to provide primary palliative care education for all physicians engaged in cancer treatment. However, the effect of PEACE program on participants was uncertain. Methods: We conducted web-based surveys for physicians belonging to the Japan Lung Cancer Society and assessed outcomes of the PEACE program across three domains: knowledge, practices, and difficulties regarding palliative care by using the palliative care knowledge questionnaire for PEACE (PEACE-Q), Palliative Care self-reported Practice Scale (PCPS), and the Palliative Care Difficulties Scale (PCDS), respectively. All of these instruments were already validated in previous studies. Results: In February 2015, the survey was distributed to 5300 physicians and 923 of those surveyed including 455 respiratory physicians, 345 pulmonary surgeons, and 35 medical oncologist responded to all questionnaires. The result of PEACE-Q, PCPS, and PCDS (low score is better) were significantly superior in physicians who had participated in the PEACE program (n = 519) compared with non-participants (n = 404) (28.0 vs. 24.5, 71.8 vs. 67.1, and 34.4 vs. 36.9, respectively). The PEACE participants made significantly better scores than non-participants in all domains of PEACE-Q (philosophy of palliative care, cancer pain, side effects of opioids, dyspnea, nausea and vomiting, psychological distress, delirium, communication, and community-based palliative care) and PCPS (pain, dyspnea, delirium, dying-phase care, communication, and patient- and family-centered care), and 3 domains of PCDS (alleviation of symptoms, expert support, and communication with the patient and family). Conclusions: The PEACE program improved knowledge and practice of palliative care in lung cancer specialists in Japan.
APA, Harvard, Vancouver, ISO, and other styles
3

Kawamoto, Terufumi, Naoki Nakamura, Tetsuo Saito, Ayako Tonari, Hitoshi Wada, Hideyuki Harada, Hikaru Kubota, et al. "Palliative brachytherapy and external beam radiotherapy for dysphagia from esophageal cancer: a nationwide survey in Japan." Japanese Journal of Clinical Oncology 51, no. 6 (February 24, 2021): 950–55. http://dx.doi.org/10.1093/jjco/hyab015.

Full text
Abstract:
Abstract Background International guidelines recommend brachytherapy for patients with dysphagia from esophageal cancer, whereas brachytherapy is infrequently used to palliate dysphagia in some countries. To clarify the availability of palliative treatment for dysphagia from esophageal cancer and explain why brachytherapy is not routinely performed are unknown, this study investigated the use of brachytherapy and external beam radiotherapy for dysphagia from esophageal cancer. Methods Japanese Radiation Oncology Study Group members completed a survey and selected the treatment that they would recommend for hypothetical cases of dysphagia from esophageal cancer. Results Of the 136 invited facilities, 61 completed the survey (44.9%). Four (6.6%) facilities performed brachytherapy of the esophagus, whereas brachytherapy represented the first-line treatment at three (4.9%) facilities. Conversely, external beam radiotherapy alone and chemoradiotherapy were first-line treatments at 61 and 58 (95.1%) facilities, respectively. In facilities that performed brachytherapy, the main reason why brachytherapy of the esophagus was not performed was high invasiveness (30.2%). Definitive-dose chemoradiotherapy with (≥50 Gy) tended to be used in patients with expected long-term survival. Conclusions Few facilities routinely considered brachytherapy for the treatment of dysphagia from esophageal cancer in Japan. Conversely, most facilities routinely considered external beam radiotherapy. In the future, it will be necessary to optimize external beam radiotherapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Shinjo, Takuya, Tatsuya Morita, Daisuke Kiuchi, Masayuki Ikenaga, Hirofumi Abo, Sayaka Maeda, Satoru Tsuneto, and Yoshiyuki Kizawa. "Japanese physicians’ experiences of terminally ill patients voluntarily stopping eating and drinking: a national survey." BMJ Supportive & Palliative Care 9, no. 2 (November 8, 2017): 143–45. http://dx.doi.org/10.1136/bmjspcare-2017-001426.

Full text
Abstract:
ObjectivesVoluntarily stopping eating and drinking (VSED) could be regarded as a patients’ own non-treatment decision that hastens death, which involves patients voluntarily forgoing food and liquid until death. The aims of this study were to investigate the experience of home hospice physicians and palliative care specialists who care for patients during VSED in Japan, and their opinions on continuous deep sedation (CDS) as a means to relieve patient symptoms during VSED.Methods219 home hospice physicians and 695 palliative care specialists across Japan were surveyed by mail questionnaire in 2016.ResultsA total of 571 (62%) responses were analysed. A total of 185 (32%) had experience of patients who selected VSED. In response to questions about CDS to provide relief to patients during VSED, the number of physicians who replied that CDS was acceptable was 88 (15%).ConclusionsIn Japan, 32% of physicians surveyed replied that they had experience of caring for patients during VSED in a clinical setting and 15% considered CDS acceptable.
APA, Harvard, Vancouver, ISO, and other styles
5

Nakamura, Yoshiaki, Kohei Shitara, and Jeeyun Lee. "The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia." American Society of Clinical Oncology Educational Book, no. 41 (June 2021): e166-e173. http://dx.doi.org/10.1200/edbk_321247.

Full text
Abstract:
Gastric cancer is a major global health burden, especially when patients are diagnosed with recurrent or metastatic gastric cancer. Despite recent advances in treatment options with palliative chemotherapy, the median overall survival of patients with gastric cancer remains within 1 or 2 years after the diagnosis of metastatic disease. Gastric cancer is significantly more prevalent in eastern Asia (e.g., Japan and Korea). Next-generation sequencing is rapidly being adopted as part of clinical practice in Korea and Japan, especially in patients with gastric cancer. Approximately 10% to 15% of the patients with gastric cancer who undergo next-generation sequencing of their tumor specimen are allocated to target-matched clinical trials in Japan and Korea. In Japan and Korea, a cell-free DNA next-generation sequencing panel is also actively being investigated as an alternative next-generation sequencing test for patients with gastric cancer, which may reflect the tumor heterogeneity of gastric cancer. In Japan and Korea, multiple biomarkers, such as HER2, mismatch repair, Epstein-Barr virus, PD-L1 (combined positive score), EGFR, FGFR2, and CLDN18.2, are routinely assessed through immunohistochemistry or in situ hybridization before initiation of the first-line treatment in all patients with gastric cancer. Most tertiary cancer centers in Korea routinely perform HER2, mismatch repair, Epstein-Barr virus, and PD-L1 next-generation sequencing before palliative chemotherapy in patients with gastric cancer. Biomarker evaluation for all patients with metastatic gastric cancer enables clinicians to identify available biomarker-based clinical trials early during the course of treatment, which expands treatment opportunities while patients are medically fit for clinical trials, if available. Comprehensive genomic profiling using a tissue or circulating tumor DNA next-generation sequencing panel is considered necessary during second-line or subsequent treatment. It is hoped that a comprehensive molecular profiling strategy will facilitate greater use of precision medicine through molecularly targeted therapies for patients with gastric cancer in the near future.
APA, Harvard, Vancouver, ISO, and other styles
6

Yamakawa, Jun-ichi, Yoshiharu Motoo, Junji Moriya, Masao Ogawa, Hiroaki Uenishi, Sumiyo Akazawa, Toshiyuki Sasagawa, Matomo Nishio, and Junji Kobayashi. "Significance of Kampo, Traditional Japanese Medicine, in Supportive Care of Cancer Patients." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–10. http://dx.doi.org/10.1155/2013/746486.

Full text
Abstract:
The current standard treatment for cancer is a multidisciplinary therapy whereby various types of treatment are properly combined. Chemotherapy with multiple anticancer drugs is now common, and traditional, complementary, and alternative therapies are adopted as supportive measures. Medical care in Japan is distinguished by the ability for patients to access both Western and Kampo medical cares at the same time. There is a high degree of trust in the safety of Kampo therapies because they are practiced by medical doctors who are educated with fundamental diagnosis of Western medicine. Highly reliable clinical studies are being published, demonstrating that palliative or supportive care for cancer patients using Kampo preparations alleviates adverse effects of chemotherapy or radiotherapy. This paper reports the circumstances around cancer care in Japan where traditional therapeutic Kampo formulas are used for patients undergoing cancer treatment with cutting-edge chemotherapy, specifically to alleviate adverse effects of anticancer drugs.
APA, Harvard, Vancouver, ISO, and other styles
7

Funakoshi, Taro, Takahiro Horimatsu, Michio Nakamura, Koichi Shiroshita, Koichi Suyama, Masashi Mukoyama, Takuro Mizukami, et al. "Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan." ESMO Open 3, no. 2 (February 2018): e000301. http://dx.doi.org/10.1136/esmoopen-2017-000301.

Full text
Abstract:
BackgroundCancer is a major cause of death in patients undergoing haemodialysis. However, information about the actual clinical practice of chemotherapy for patients with cancer undergoing haemodialysis is lacking. We conducted a nationwide survey using questionnaires on the clinical practice of chemotherapy for such patients.Patients and methodsThe nationwide survey included patients undergoing haemodialysis who were subsequently diagnosed with cancer in 20 hospitals in Japan from January 2010 to December 2012. We reviewed their clinical data, including cancer at the following primary sites: kidney, colorectum, stomach, lung, liver, bladder, pancreas and breast. The questionnaires consisted of the following subjects: (1) patient characteristics; (2) regimen, dosage and timing of chemotherapy; and (3) clinical outcome.ResultsOverall, 675 patients were registered and assessed for main primary cancer site involvement. Of 507 patients with primary site involvement, 74 patients (15%) received chemotherapy (44 as palliative chemotherapy and 30 as perioperative chemotherapy). The most commonly used cytotoxic drugs were fluoropyrimidine (15 patients), platinum (8 patients) and taxane (8 patients), and the dosage and timing of these drugs differed between institutions; however, the dosage of molecular targeted drugs (24 patients) and hormone therapy drugs (15 patients) was consistent. The median survival time of patients receiving palliative chemotherapy was 13.0 months (0.1–60.3 months). Three patients (6.8%) died from treatment-related causes and nine patients (20%) died of causes other than cancer. Of the 30 patients who received perioperative chemotherapy, 6 (20%) died of causes other than cancer within 3 years after the initiation of chemotherapy.ConclusionAmong the haemodialysis patients with cancer who received chemotherapy, the rates of mortality from causes other than cancer might be high for both palliative and perioperative chemotherapy. Indications for the use of chemotherapy in patients undergoing haemodialysis should be considered carefully.
APA, Harvard, Vancouver, ISO, and other styles
8

Tsuboi, Rie, Mihoko Sugishita, Hirohisa Hirakawa, and Yuichi Ando. "Spiritual pain and care needs of elderly cancer patients facing palliative chemotherapy decision-making: Qualitative study." Journal of Clinical Oncology 36, no. 34_suppl (December 1, 2018): 25. http://dx.doi.org/10.1200/jco.2018.36.34_suppl.25.

Full text
Abstract:
25 Background: Although the number of elderly cancer patients who require chemotherapy has increased, few studies have investigated the process of palliative chemotherapy decision-making and care needs of elderly patients with advanced cancer. Methods: The study was conducted at Nagoya University Hospital in Japan from April to October 2017. Face-to-face interviews were conducted with patients over 70 with advanced cancer (n = 15, median age = 77 years, range 70 - 82) who made decisions of palliative chemotherapy initiation within 6 months. Patients’ families and physicians were also interviewed individually. Interview transcripts were qualitatively analyzed using a deductive-inductive approach. Results: Four main themes emerged: physician’s awareness of paternalism, training of communication about serious news, spiritual-care needs assessment, and support with the team. Both the patients and the physicians felt the necessity for physicians’ paternalism in patients’ decision-making. The physicians found treatment decision-making for elderly patients difficult because of the patients’ diversities. Patients had spiritual pains from the time of diagnosis and they continued throughout treatment periods. They fought the illness with the support of surroundings as a team. Conclusions: Paternalism was emphasized from both elderly patients and physicians in palliative chemotherapy decision-making. Improvement of the communication skills of physicians was needed. Patients had spiritual-care needs beginning with the early phase of the treatments and fought as a team with their supporters, including physicians against the cancer. Physicians should be aware of that and be actively involved in whole-patient care.
APA, Harvard, Vancouver, ISO, and other styles
9

Kawamura, Atsufumi, Junji Koyama, Nobuyuki Akutsu, and Mai Azumi. "DIPG-12. PALLIATIVE TREATMENT FOR DIPG (DIFFUSE INTRINSIC PONTINE GLIOMA) AT KOBE CHILDREN’S HOSPITAL IN JAPAN." Neuro-Oncology 20, suppl_2 (June 2018): i51. http://dx.doi.org/10.1093/neuonc/noy059.105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tei, Yo, Tatsuya Morita, Toshimichi Nakaho, Chizuko Takigawa, Akiko Higuchi, Akihiko Suga, Tsukasa Tajima, et al. "Treatment Efficacy of Neural Blockade in Specialized Palliative Care Services in Japan: A Multicenter Audit Survey." Journal of Pain and Symptom Management 36, no. 5 (November 2008): 461–67. http://dx.doi.org/10.1016/j.jpainsymman.2007.11.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Palliative treatment Japan"

1

Majima, Tomoko, Junko Kusunoki, and Tomoko Otsuka. "The Role of the Home-Visit Nursing System in the Treatment of Terminal Cancer Patients in Japan." In Palliative Care for Chronic Cancer Patients in the Community, 543–47. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-54526-0_49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hisashige, Akinori. "Recent Trend and Problems of Health Economics in Japan: Application of Clinical Economics to the Treatment for Cancers and Intractable Diseases." In Current Perspectives and Future Directions in Palliative Medicine, 155–66. Tokyo: Springer Japan, 1998. http://dx.doi.org/10.1007/978-4-431-68494-7_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Palliative treatment Japan' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography